Sumatriptan/naproxen sodium combination for the treatment of migraine

Expert Review of Neurotherapeutics

Volumn 8, Issue 9, 2008, Pages 1289-1297

  Cleves, Catalina ^b   Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Pediatric Neurology   (United States)

Author keywords

Migraine; Naproxen sodium; NSAID; Sumatriptan; Triptan

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN; TOLFENAMIC ACID; TREXIMET; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BIOEQUIVALENCE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MONOTHERAPY; MUSCLE TIGHTNESS; NAUSEA; OPTIMAL DRUG DOSE; PARESTHESIA; PHARMACODYNAMICS; PLEURITIC CHEST PAIN; REVIEW; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THROAT TIGHTNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNITED STATES; VASOCONSTRICTION; VIRUS MYOCARDITIS; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; MIGRAINE DISORDERS; NAPROXEN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 51149108748     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.9.1289     Document Type: Review

References (40)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia 24(Suppl. 1), 1-154 (2004). •• International standard of care for headache diagnostic criteria.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646-657 (2001). •• Third in a pivotal series of epidemiologic studies on headache in the USA.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159(8), 813-818(1999).
4. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39(Suppl. 2), 20-26 (1999). •• Defining patient needs in acute migraine treatment.
5. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 US Centers in US and Sweden. Headache 47(4), 475-479 (2007).
6. Kori SH, Sandefer EP, McDonald SA et al. Improved disintegration and gastric emptying of sumatriptan tablets formulated with RT Technology. Presented at: 57th American Academy of Neurology Annual Meeting. FL, USA, 9-16 April, 2005 (Abstract P06.031).
7. Kori SH, McDonald SA, Page RC et al. Gastric transit and absorption of reformulated and conventional sumatriptan tablets in migraineurs both during and outside of a migraine attack: evaluation by gastric scintigraphy. Presented at: 58th American Academy of Neurology Annual Meeting. CA, USA, 1-6 April 2006 (Abstract P06.184).
8. Walls C, Lewis A, Bullman J et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin. 20(6), 803-809 (2004).
9. Kori S, Byrd SC, Doll WJ et al. Gastric transit and absorption of sumatriptan and naproxen form a fixed single-tablet sumatriptan RT technology 85 mg and naproxen sodium 500 mg in migraineurs both during and outside a migraine attack: evaluation by gastric scintigraphy. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 7-11 June 2007 (Abstract F02).
10. Coulie B, Tack J, Maes B, Geypens B, De Roo M, Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am. J. Physiol. 272(4 Pt 1), G902-G908 (1997).
11. Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment. Pharmacol. Ther. 6(6), 685-691 (1992).
12. GlaxoSmithKline Sumatriptan Periodic safety Update Report, 01 April 2005 to September 30th 2005. Document number GM/2005/00431/00.
13. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur. Neurol. 31(5), 300-305 (1991).
14. Cottrell CK, Gibson JG, Waller SW, Holroyd KA, O'Donnell FJ. The timing of triptan use and its effect on migraine-related disability. Presented at: 10th Congress of the International Headache Society and the American Association for the Study of Headache Scientific Meeting, NY, USA, June 2001 (Abstract P1-F8).
15. Volans GN. Migraine and drug absorption. Clin. Pharmacokine 3(4), 313-318(1978).
16. Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 8(3), 139-147 (1988).
17. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 4(4), 253-263 (1984).
18. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br. J. Clin. Pharmacol. 30(3), 405-409 (1980).
19. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123(8), 1703-1709 (2000).
20. Ferrari MD, James MH, Bates D et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14(5), 330-338 (1994).
21. Lipton RB, Pascual J, Goadsby PJ et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache 41(8), 754-763 (2001). •• Classic study suggesting benefit and synergy of triptan plus a NSAID.
22. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsichiatr. 58(2-B), 428-430 (2000).
23. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45(8), 983-991 (2005).
24. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreased migraine recurrence when used with sumatriptan. Cephalalgia 19(3), 186-187 (1999).
25. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22(4), 309-312 (2002).
26. Krymchantowski VS, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the treatment of migraine. BMC Neurol. 4, 10 (2004).
27. Brandes JL, Kudrow D, Stark SR et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297(13), 1443-1454 (2007). •• Two Phase III regulatory submission trials on the sumatriptan/naproxen sodium combination tablet.
28. Sheftell F, Winner P, Finkel A, Lener S, White J, Nelsen A. Consistent sustained efficacy across 4 migraine attacks with a fixed single-tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg (SumaRT/Nap). Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6-11 June 2007 (Abstract No F44).
29. Winner P, Aurora S, Matthew N, Kori S, Lener S, Nelsen A. Migraine free rates across four attacks treated with a fixed single-tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg vs. placebo. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6-11 June 2007 (Abstract No S73).
30. Smith T, Blumenthal H, Diamond M et al. Sumatriptan/naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache 47(5), 683-692 (2007).
31. Lipton R, Adelman J, Aurora S, Lener M, White A, Nelsen A. Within person consistency across 4 migraine attacks of a fixed single tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg (sumaRT/nap). Presented at: 59th American Academy of Neurology Annual Meeting. MA, USA, 28 April-5 May 2007 (Abstract No S25.001).
32. Diamond M, Martin V, Ballard J et al. Patient satisfaction following treatment of a menstrually related migraine and dysmenorrhea with a single-tablet formulation of sumatriptan RT technology and naproxen sodium. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6-11 June 2007 (Abstract No S09).
33. Cady R, Mannix L, Diamond M et al. Work productivity and disability in menstrually related migraines and dysmenorrhea following treatment with a single-tablet formulation of sumatriptan RT technology (and naproxen sodium. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6-11 June 2007 (Abstract No S13).
34. Silberstein S, Goldstein J, Mannix LK et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 71(2), 114-121 (2008).
35. Winner P, Cady RK, Rouff GE et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin. Proc. 82(1), 61-68 (2007).
36. Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur. Neurol. 33(4), 310-315 (1993).
37. Dodick D, Lipton RB, Martin V et al. Triptan cardiovascular safety expert panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(50), 414-425 (2004). •• Most important and complete discussion of triptan cardiovascular safety with a consensus statement: the standard of care.
38. Sheftell F, O'Quinn S, Watson C, Pait D, Winter P. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 40(2), 103-110 (2000).
39. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostagl andins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20(10), 907-918 (2000).
40. Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62(5), 788-790 (2004).